KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $118000.0.

  • Aquestive Therapeutics' Change in Accured Expenses rose 11782.48% to $118000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year increase of 2145.8%. This contributed to the annual value of -$1.5 million for FY2024, which is 4067.59% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Change in Accured Expenses stood at $118000.0, which was up 11782.48% from $600000.0 recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Change in Accured Expenses ranged from a high of $1.9 million in Q2 2022 and a low of -$4.0 million during Q1 2022
  • Its 5-year average for Change in Accured Expenses is -$489000.0, with a median of -$25000.0 in 2022.
  • The largest annual percentage gain for Aquestive Therapeutics' Change in Accured Expenses in the last 5 years was 391600.0% (2023), contrasted with its biggest fall of 16029.87% (2023).
  • Quarter analysis of 5 years shows Aquestive Therapeutics' Change in Accured Expenses stood at $1.2 million in 2021, then crashed by 102.08% to -$25000.0 in 2022, then soared by 3916.0% to $954000.0 in 2023, then decreased by 3.98% to $916000.0 in 2024, then crashed by 87.12% to $118000.0 in 2025.
  • Its Change in Accured Expenses stands at $118000.0 for Q3 2025, versus $600000.0 for Q2 2025 and -$2.8 million for Q1 2025.